Prescription pricing -- United States
Label
Prescription pricing -- United States
Name
Prescription pricing
Focus
Sub focus
Actions
Incoming Resources
- The other drug war, produced and directed by Jon Palfreman and Barbara Moran ; written by Jon Palfreman
- Changes in co-pays employer-sponsored health insurance plans, 1999-2003, Beth Levin Crimmel, Amy K. Taylor, Alice M. Zawacki
- The top five outpatient prescription drugs ranked by total expense for Medicare beneficiaries, by insurance status, 2004, Marie N. Stagnitti
- Sudden price spikes in decades-old prescription drugs, inside the monopoly business model : hearing before the Special Committee on Aging, United States Senate, One Hundred Fourteenth Congress, second session, Washington, DC, March 17, 2016
- Examining prescription drug importation, a review of a proposal to allow third parties to reimport prescription drugs : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, July 25, 2002
- A prescription for savings, reducing drug costs to Medicare : hearing before the Special Committee on Aging, United States Senate, One Hundred Twelfth Congress, first session, Washington, DC, July 21, 2011
- Drug prices, the role of patents and regulatory exclusivities, Erin H. Ward, Kevin J. Hickey, Kevin T. Richards
- Tax provisions in the "Build Back Better Act", the House Ways and Means Committee's legislative recommendations, Molly F. Sherlock [and six others]
- Manufactured crisis, how better negotiation could save billions for Medicare and America's seniors
- The insular areas Medicaid cliff, oversight hearing before the Committee on Natural Resources, U.S. House of Representatives, One Hundred Sixteenth Congress, first session, Thursday, May 23, 2019
- Strategies used by adults to reduce their prescription drug costs, United States, 2013, Robin A. Cohen and Maria A. Villarroel
- The complex web of prescription drug prices, hearing before the Special Committee on Aging, United States Senate, One Hundred Sixteenth Congress, first session, Washington, DC
- Direct-to-consumer advertising, marketing, education, or deception? : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, May 8, 2008
- Negotiating a better deal, legislation to lower the cost of prescription drugs : virtual hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventeenth Congress, first session, May 4, 2021
- Replacing average wholesale price, Medicaid drug payment policy
- Pay-for-delay, how drug company pay-offs cost consumers billions : an FTC staff study
- Special report of the U.S. Senate Special Committee on Aging on the sudden price spikes in off-patent prescription drugs, the monopoly business model that harms patients, taxpayers, and the U.S. health system
- Outpatient prescription medicines, a comparison of expenditures by household-reported condition, 1987 and 2001, Marie N. Stagnitti and Mamatha Pancholi
- Lower drug costs now, expanding access to affordable health care : hearing before the Subcommittee on Health, Employment, Labor, and Pensions of the Committee on Education and Labor, U.S. House of Representatives, One Hundred Seventeenth Congress, first session, hearing held in Washington, DC, May 5, 2021
- Prescription drug pricing and negotiation, overview and economic perspectives for the Medicare prescription drug benefit : hearing before the Committee on Finance, United States Senate, One Hundred Tenth Congress, first session, January 11, 2007
- Family health care expenses, by size of family, 2002, Steven R. Machlin and Marc W. Zodet
- Prices for brand-name drugs under selected federal programs
- Would prescription drug importation reduce U.S. drug spending?
- Developments in the prescription drug market, oversight : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fourteenth Congress, second session, February 4, 2016
- The Medicare drug benefit, are private insurers getting good discounts for the taxpayer? : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, second session, July 24, 2008
- Why are some generic drugs skyrocketing in price?, hearing before the Subcommittee on Primary Health and Aging of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Thirteenth Congress, second session, on examining the pricing of generic drugs, November 20, 2014
- EpiPen price increases, how regulatory barriers inhibit pharmaceutical competition : field hearing of the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session on examining EpiPen price increases, focusing on how regulatory barriers inhibit pharmaceutical competition, October 7, 2016 (Lexington, KY)
- Drug pricing and intellectual property, the legislative landscape for the 117th Congress, Kevin J. Hickey, Kevin T. Richards, Erin H. Ward
- Outpatient prescribed medicines, a comparison of use and expenditures, 1987 and 2001, Mamatha Pancholi and Marie Stagnitti
- The truth about the drug companies, how they deceive us and what to do about it, Marcia Angell
- Drug shortages, causes, FDA authority, and policy options, Agata Dabrowska
- The cost of prescription drugs, examining the President's blueprint 'American Patients First' to lower drug prices : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fifteenth Congress, second session, on examining the cost of prescription drugs, focusing on examining the President's blueprint 'American Patients First' to lower drug prices, June 12, 2018
- DOD and VA pharmacy, progress and remaining challenges in jointly buying and mailing out drugs : report to Congressional requesters, United States General Accounting Office
- A detailed description of CBO's cost estimate for the Medicare prescription drug benefit
- Out-of-pocket cost and acquisition of prescribed medicines, United States, 1973, [Jai W. Choi]
- Ten years later, a look at the Medicare prescription drug program : hearing before the Special Committee on Aging, United States Senate, One Hundred Thirteenth Congress, first session : Washington, DC, Wednesday, May 22, 2013
- Frequently asked questions about prescription drug pricing and policy, Suzanne M. Kirchhoff, Judith A. Johnson, Susan Thaul
- No time to wait, proposals to lower prescription drug costs : hearing before the Special Committee on Aging, United States Senate, One Hundred Seventeenth Congress, second session, Phoenix, Arizona, April 12, 2022
- Medicaid prescription drugs, CMS should implement revised federal upper limits and monitor their relationship to retail pharmacy acquisition costs : report to congressional requesters
- Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005, Marie N. Stagnitti
- Prescription drugs, out-of-pocket expenses and unmet need relative to family income, 2002, Beth Levin Crimmel and Marie N. Stagnitti
- Policy implications of pharmaceutical importation for U.S. consumers, hearing before the Subcommittee on Interstate Commerce, Trade, and Tourism of the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Tenth Congress, first session, March 7, 2007
- Making health care more affordable, lowering drug prices and increasing transparency : hearing before the Subcommittee on Health, Employment, Labor and Pensions, Committee on Education and Labor, U.S. House of Representatives, One Hundred Sixteenth Congress, first session : hearing held in Washington, DC, September 26, 2019
- Generic drug user fee amendments, accelerating patient access to generic drugs : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session ... January 28, 2016
- Effects of using generic drugs on Medicare's prescription drug spending
- Prescription drug benefits: impact of Medicare HMO's use of formularies on beneficiaries, testimony before the Special Committee on Aging, U.S. Senate, statement of William J. Scanlon
- Pay-for-delay deals, limiting competition and costing consumers : hearing before the Subcommittee on Antitrust, Competition Policy and Consumer Rights of the Committee on the Judiciary, United States Senate, One Hundred Thirteenth Congress, first session, July 23, 2013
- Implementation of the Medicare drug benefit, hearing before the Subcommittee on Health of the Committee on Ways and Means, U.S. House of Representatives, One Hundred Ninth Congress, second session,May 3 and May 4, 2006
- Options for safe and effective prescription drug importation, hearing before the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Eighth Congress, second session, March 11, 2004
- The big fix, how the pharmaceutical industry rips off American consumers, Katharine Greider
Outgoing Resources
- Focus1
- Sub focus1